Catalyst Biosciences Inc (CBIO)

NASDAQ
4.610
-0.020(-0.43%)
  • Volume:
    86,481
  • Bid/Ask:
    4.610/4.630
  • Day's Range:
    4.488 - 4.650

CBIO Overview

Prev. Close
4.63
Day's Range
4.488-4.65
Revenue
5.52M
Open
4.56
52 wk Range
3.72-7.55
EPS
-3.01
Volume
86,481
Market Cap
145.22M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
292,022
P/E Ratio
-
Beta
2.01
1-Year Change
3.81%
Shares Outstanding
31,365,701
Next Earnings Date
Nov 04, 2021
What is your sentiment on Catalyst Biosciences Inc?
or
Vote to see community's results!

Catalyst Biosciences Inc News

Catalyst Biosciences Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellSell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell

Catalyst Biosciences Inc Company Profile

Catalyst Biosciences Inc Company Profile

Employees
36

Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.

Read More
  • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
    0
    • hope that in long term it will rise
      0
      • Phase 1/2 completion of dosing announced June 14, 2017 with data due by the end of September.. Data will be excellent! The stock will rock once again!
        0
        • To holders of CBIO: Patience will pay off. Between now and December we should have a major event that would restore the fair price to this stock.
          0
          • Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program. . 8:01 am ET September 11, 2017 (Globe Newswire) Print
            0
            • CBIO is warming up to something. Maybe good news is in the way. I feel something good is coming
              0
              • why are you selling your shares cheep. Some one is accumulating for the big day.
                0
                • Watch out for $CBIO as secondary offering lock-up expires tomorrow 7/6/17
                  0
                  • Something I read from an analyst opinion column today about this . . This is a great news for $CBIO for being able to partner with "ISU Abxis"ISU Abxis is the beggest Biotech ion Korea with annual revenue of $30B.. Furthermore, they are doing some fantastic blood cancer work. If they agreed to $CBIO data, that means something....
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.